BPC-157 vs TB-500: Research Comparison

Fast Comparison: BPC-157 vs TB-500

What Is BPC-157?

BPC-157 (Body Protection Compound 157) is a 15-amino-acid synthetic pentadecapeptide (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, CAS 137525-51-0, MW 1419.55 g/mol) derived from a stable fragment of a protein originally isolated from human gastric juice.^[1]

Its preclinical signal centres on tissue-repair models involving the nitric-oxide system, VEGF/eNOS angiogenic signalling, and FAK-paxillin growth-factor activity. The recurring rodent phenotype is improved perfusion and accelerated stromal repair across tendon, ligament, gut-mucosal, and vascular injury models.^[1] The deeper mechanism walk-through lives in the dedicated BPC-157 healing peptide review.

It is supplied as a 10mg lyophilized research vial at >99% HPLC purity for in-vitro laboratory research. It is not an approved medicine and there is no established human dosage or protocol.

What Is TB-500?

TB-500 is the marketed name for a synthetic short-fragment peptide derived from the active region of Thymosin Beta-4 (Tβ4), the principal G-actin-sequestering peptide in mammalian cells. Full-length native Tβ4 is a 43-amino-acid acidic peptide (reference CAS 77591-33-4, reference MW 4,963.4 g/mol); the peptide widely sold under the TB-500 label is a synthetic shorter fragment that retains the central actin-binding motif and the N-terminal AcSDKP sequence rather than the full 43-residue protein.^[4]

Its preclinical signal centres on actin-cytoskeleton dynamics: Tβ4 binds monomeric G-actin in a 1:1 complex and modulates the G-actin / F-actin equilibrium during cytoskeletal remodelling, which underlies lamellipodial protrusion, fibroblast migration, and keratinocyte sheet movement.^[2] A distinct strand involves the AcSDKP terminal fragment, a separately characterised anti-fibrotic and haematopoietic regulator.^[5] The full mechanism walk-through lives in the dedicated TB-500 (Thymosin Beta-4 fragment) review.

It is supplied as a 10mg lyophilized research vial at >99% HPLC purity for in-vitro laboratory research.

Mechanism-by-Mechanism Contrast

The cleanest way to separate the two compounds is by the biology they touch. The pathway split is non-overlapping:

• BPC-157 — the vascular and stromal lane. Rodent studies report that BPC-157 modulates the nitric-oxide system, upregulates VEGFR2 and downstream eNOS-mediated angiogenic signalling in endothelial-cell models, and activates focal-adhesion kinase / paxillin phosphorylation in tendon and fibroblast preparations. The phenotype is improved perfusion and accelerated stromal repair.^[1]
• TB-500 — the actin-cytoskeleton lane. Native Thymosin Beta-4 binds monomeric G-actin in a 1:1 complex, maintains the cytoplasmic G-actin pool, and modulates the G-actin / F-actin equilibrium during cytoskeletal remodelling. Functionally this is the building block of lamellipodial protrusion, fibroblast migration, and keratinocyte sheet movement — the cell-migration component of wound re-epithelialisation. A distinct mechanistic strand involves the AcSDKP terminal fragment, an endogenous regulator of haematopoietic stem-cell cycling and a separately characterised anti-fibrotic peptide.^[2][5]

Read side by side, BPC-157 modulates the vascular and growth-factor signal underneath a repair site, while TB-500 modulates the cytoskeletal-migration signal at the cell level. That is why the two are not substitutes: a research design that needs an angiogenic / nitric-oxide endpoint is a BPC-157 question, and a design that needs an actin-binding or cell-migration endpoint is a TB-500 question.

When Researchers Study Each

BPC-157 belongs in studies asking how a cytoprotective, gastric-protein-derived peptide changes vascular and stromal repair signalling. Relevant endpoints include VEGFR2 / eNOS angiogenic signalling, nitric-oxide-system modulation, FAK-paxillin phosphorylation, and tendon, ligament, gut-mucosal, or vascular injury models. The deeper mechanism and the Lee and Burgess 2025 first human IV pilot are covered in the BPC-157 healing peptide review.

TB-500 belongs in studies asking how a Thymosin Beta-4 fragment changes actin-cytoskeleton dynamics and cell migration. Relevant endpoints include G-actin sequestration, lamellipodial protrusion, fibroblast and keratinocyte migration, endothelial tube formation, and AcSDKP-mediated anti-fibrotic signalling. Note the labelling distinction: the marketed TB-500 fragment is not the same regulatory entity as the full-length Tβ4 used in the RegeneRx RGN-259 ophthalmic programme, so full-length Tβ4 mechanism papers do not map 1:1 onto a TB-500 vial.^[4] The TB-500 review covers the fragment-vs-full-length distinction and the ARISE ophthalmology status in full.

For product-format details, compare the BPC-157 10mg research vial and the TB-500 10mg research vial; both ship from the same Dubai stock under the same 2-8°C cold-chain handling.

Evidence Base and Limits

Both compounds are preclinical-dominant, and neither has a late-stage human musculoskeletal trial. For BPC-157, the only published human data is the Lee and Burgess 2025 two-subject IV pilot in healthy adults (PMID 40131143); everything else in the BPC-157 literature is rodent and in-vitro work.^[3]

For Thymosin Beta-4, the clearest human record is the RegeneRx RGN-259 ARISE Phase 3 dry-eye programme — a preservative-free 0.1% Tβ4 eye drop with mixed sign/symptom endpoints and no FDA approval as of April 2026. Two caveats matter: that programme tests full-length Tβ4, not the marketed TB-500 fragment, and a ClinicalTrials.gov search returns no Phase 2 or Phase 3 human musculoskeletal trial for TB-500 or the fragment.^[2]

The honest summary: both are well-characterised at the preclinical level in different lanes, and both have thin-to-absent late-stage human records. Any source presenting either as a finished, validated human therapy is going past the published evidence.

Why They Are Often Studied Together

Because the pathways are non-overlapping, investigators sometimes co-administer the two in animal-model repair work: BPC-157 contributes the vascular and growth-factor signal while TB-500 contributes the actin-driven cell-migration signal. The rationale is mechanistic complementarity, not published synergy — synergy is a specific pharmacological claim that requires combination data showing the joint effect exceeds the additive sum, and no such combination dataset has been published for BPC-157 + TB-500.^[1][2]

Remy supplies a co-formulated BPC-157 + TB-500 5mg + 5mg blend vial for researchers running fixed 1:1 mass-ratio co-administration protocols, while the separate BPC-157 and TB-500 vials suit investigators who need independent dose control. The full combination evidence review — the empty human combination record, the complementary-vs-synergy distinction, and the FDA PCAC compounding backdrop — is in the BPC-157 + TB-500 blend mechanism & synergy article.

Reconstitution & Handling

Both compounds are handled like other short research peptides, and the storage chemistry is the same for either vial:

• Storage of the lyophilisate. 2-8°C protected from light for routine use; -20°C for long-term storage. The UAE summer climate makes documented cold-chain handling from arrival to bench-side important — short ambient excursions during last-mile delivery are the most common stability risk.
• Reconstitution. Reconstitute with bacteriostatic water (0.9% benzyl alcohol as preservative) at the volume dictated by the research protocol. Add the diluent down the inner wall of the vial and let it dissolve passively; do not shake.
• Volume math. Each compound is supplied as a 10mg lyophilized vial; the reconstitution calculator documents the standard per-volume working-concentration math for research use.
• Post-reconstitution storage. 2-8°C with use inside the research-protocol working window; reconstituted research-grade peptide solutions are typically used within 2-4 weeks of reconstitution, though stability programmes vary by laboratory.

This is reconstitution math for research-vial handling. The page provides no human-use dosing or veterinary instructions and is not a clinical-protocol document.

BPC-157 & TB-500 Research Access in Dubai & UAE

For a UAE-based research catalog operating under MoHAP Circular 17/2022, both compounds belong in the category of healing-and-repair research peptides — each supplied as a 10mg lyophilized research vial at >99% HPLC purity, with cold-chain handling and reconstitution using bacteriostatic water for in-vitro work. The BPC-157 10mg research vial and TB-500 10mg research vial ship from the same Dubai stock under the same 2-8°C cold-chain, with same-day Dubai dispatch on orders before 4 PM and next-day cold-chain delivery to the rest of the UAE.

Researchers who want a fixed 1:1 co-administration format can use the co-formulated BPC-157 + TB-500 blend vial instead; the combination question itself is reviewed in the blend mechanism & synergy article. Material is supplied strictly for in-vitro laboratory research. It is not framed for human use, not framed for veterinary use, and not framed as a treatment.